Hansa Biopharma submitted an application for full marketing authorization to the European Medicines Agency.
3 reports, 2 independent
Updated May 27
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 3
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Hansa Biopharma submitted an application for full marketing authorization to the European Medicines Agency.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Hansa Biopharma is seeking approval for its drug Idefirix in various markets, with SERB handling commercialization in EU member states.Sub-event
Hansa Biopharma applied for full marketing authorization with the EMA.1 source
Hansa Biopharma achieved conditional product approval based on Phase 3 trial results.1 source
Keep exploring
The entities involved
-
Hansa Biopharma
company in Lund, Sweden
Nothing else this week.
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- Both the FDA and the European Medicines Agency govern drug approval processes.
- OS Therapies, Inc. is seeking regulatory approval from the European Medicines Agency for a new cancer treatment.
- AbbVie submitted an application for risankizumab approval to the European Medicines Agency.
- The FDA and European Medicines Agency are harmonizing regulatory review of drug applications.
- EMA validated marketing authorization and FDA accepted NDA for Pharvaris N.V.'s lead drug.